Beyond registration - Measuring the public-health potential of new treatments for malaria in Africa

Lancet Infectious Diseases

Volumn 6, Issue 1, 2006, Pages 46-52

  Lang, Trudie ^a,g   Hughes, Dyfrig ^b   Kanyok, Tom ^c   Kengeya Kayondo, Jane ^c   Marsh, Vicki ^d   Haaland, Ane ^e   Pirmohamed, Munir ^f   Winstanley, Peter ^f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BANGOR UNIVERSITY   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e Haaland Communication   (Norway)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CHLORPROGUANIL PLUS DAPSONE;

AFRICA; CLINICAL TRIAL; DISEASE REGISTRY; DRUG DOSE; DRUG EFFICACY; DRUG INFORMATION; DRUG PACKAGING; DRUG PROGRAM; DRUG RESISTANCE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEALTH EDUCATION; HEALTH PROGRAM; HUMAN; MALARIA; MALARIA CONTROL; PRACTICE GUIDELINE; PREGNANT WOMAN; PRIORITY JOURNAL; PROSPECTIVE PRICING; REVIEW;

EID: 29244452931     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70326-1     Document Type: Note

References (21)

1. WHO World health report 2002 WHO Geneva
2. SD Foster Pricing, distribution, and use of antimalarial drugs Bull World Health Organ 69 1991 349 363
3. F Castro-Leal, J Dayton, L Demery, K Mehra Public spending on health care in Africa: do the poor benefit? Bull World Health Organ 78 2000 66 74
4. T Lang, B Greenwood The development of Lapdap, an affordable new treatment for malaria Lancet Infect Dis 3 2003 162 168
5. R Widdus Public-private partnerships for health: their main targets, their diversity, and their future directions Bull World Health Organ 79 2001 713 720
6. D Ross-Degnan, SB Soumerai, PK Goel The impact of face-to-face educational outreach on diarrhoea treatment in pharmacies Health Policy Plan 11 1966 308 318
7. DA Revicki, L Frank Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies Pharmacoeconomics 15 1999 423 434
8. AA Amin, DA Hughes, V Marsh The difference between effectiveness and efficacy of antimalarial drugs in Kenya Trop Med Int Health 9 2004 967 974
9. VM Marsh, WM Mutemi, J Muturi Changing home treatment of childhood fevers by training shop keepers in rural Kenya Trop Med Int Health 4 1999 383 389
10. MD Rawlins Pharmacovigilance: paradise lost, regained or postponed? J R Coll Physicians Lond 29 1995 41 49
11. FO Ajayi, H Sun, J Perry Adverse drug reactions: a review of the relevant factors J Clin Pharmacol 40 2000 1093 1101
12. M Pirmohamed, J Darbyshire Collecting and sharing information about harms BMJ 329 2004 6 7
13. R Edwards Competing in drug safety Nature 415 2002 670 672
14. PC Waller, SM Wood, MJ Langman, AM Breckenridge, MD Rawlins Review of company postmarketing surveillance studies BMJ 6 1992 1470 1472
15. IR Edwards, JK Aronson Adverse drug reactions: definitions, diagnosis, and management Lancet 356 2000 1255 1259
16. E Molyneux, R Brogan, G Mitchell, S Gove Children's weights: guess or measure by tape? Lancet 354 1999 1616
17. A Montresor, D Engles, L Chitsulo, DA Bundy, S Brooker, L Savioli Development and validation of a 'tablet pole' for the administration of praziquantel in sub-Saharan Africa Trans R Soc Trop Med Hyg 95 2001 542 544
18. ND Alexander, SN Cousens, H Yahaya, A Abiose, BR Jones Ivermectin dose assessment without weighing scales Bull World Health Organ 71 1993 361 366
19. K Yeboah-Antwi, JO Gyapong, IK Asare, G Barnish, DB Evans, S Adjei Impact of prepackaging antimalarial drugs on cost to patients and compliance with treatment Bull World Health Organ 79 2001 394 399
20. B Greenwood, T Mutabingwa Malaria in 2002 Nature 415 2002 670 672
21. A Alloueche, W Bailey, S Barton Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial Lancet 363 2004 1843 1848